Scarica l'app Stockscreener
20.59
4.36%
0.86
Dopo l'orario di chiusura:
20.70
0.11
+0.53%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SMMT Giù?
Forum
Previsione
Summit Therapeutics Inc Borsa (SMMT) Ultime notizie
Summit Therapeutics Inc. Company Investigated by the Portnoy Law Firm - GlobeNewswire
Summit Therapeutics Inc. Company Investigated by the Portnoy Law Firm - GlobeNewswire Inc.
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listi - GuruFocus
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Brown-Forman Corporation - GlobeNewswire Inc.
Summit Therapeutics Expands Team with $1.2M Stock Options Package for 7 New Hires - Stock Titan
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Truist Sticks to $35 Target on Summit (SMMT) Despite Shifting Deal Landscape - MSN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc.SMMT - FinancialContent
Summit Therapeutics Shares Slip Following Mixed Results from Lung Cancer Trial - MSN
Summit Therapeutics to Participate in the 46th Annual Goldman Sa - GuruFocus
Summit Therapeutics Readies Major Ivonescimab Development Update for Goldman Sachs Healthcare Conference - Stock Titan
Summit Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference - Business Wire
Why Summit Therapeutics Inc. (SMMT) Crashed On Wednesday - Insider Monkey
2 Soaring Stocks Wth More Upside Potential - AOL.com
Investors Are Dumping These 10 Stocks - Insider Monkey
Why Summit Therapeutics Inc. (SMMT) Crashed Last Week - MSN
Why Summit Therapeutics Inc. (SMMT) Skyrocketed On Tuesday - MSN
Why is Summit stock in selloff after late-stage trial data for lead asset? - MSN
Summit Therapeutics: What's This Ivonescimab Rollercoaster - Nasdaq
10 Stocks Leaving Wall Street in The Dust - Insider Monkey
Explaining Summit's Fall Despite Positive Data In EGFR-Positive Lung Cancer (NASDAQ:SMMT) - Seeking Alpha
Down 36.7% in 4 Weeks, Here's Why Summit Therapeutics (SMMT) Looks Ripe for a Turnaround - Yahoo Finance
Summit Therapeutics: Market Overreaction Creates Opportunity (NASDAQ:SMMT) - Seeking Alpha
Summit Therapeutics Stock Nosedives on Mixed NSCLC Study Results - sharewise
Summit Therapeutics (SMMT) Gains Attention Following Positive Phase III Trial Results | SMMT Stock News - GuruFocus
SMMT: Summit Therapeutics' Market Outperform Rating Reiterated by JMP Securities | SMMT Stock News - GuruFocus
SMMT, MTDR, FTAI: 3 High-Potential Russell 2000 Stocks with Strong Buy Ratings - TipRanks
Is Summit Therapeutics Stock A Buy After Its Recent 30% Fall? - Forbes
Summit Therapeutics: What’s This Ivonescimab Rollercoaster - Trefis
3 No-Brainer Healthcare Stocks to Buy in June - AOL.com
Is Beaten-Down Summit Therapeutics Stock a Bad-News Buy? - AOL.com
Five things for pharma marketers to know: Monday, June 2, 2025 - Medical Marketing and Media
These 10 Stocks Just Rocked The Market - Insider Monkey
Why Summit Therapeutics Inc. (SMMT) Crashed On Friday - Insider Monkey
Summit Therapeutics Announces Positive Phase III Trial Results - TipRanks
U.S. Markets Ended Friday Mixed As Ulta Beauty Led, Summit Therapeutics Lagged - Barron's
Summit Therapeutics (SMMT) Faces Setback After Trial Results - GuruFocus
Summit Therapeutics (SMMT) Stock Plunges on Trial Data Release - GuruFocus
Summit Therapeutics: Moving Stock To 'Hold' Rating After Phase 3 HARMONi Data Release - Seeking Alpha
Summit stock in selloff post cancer trial data (SMMT:NASDAQ) - Seeking Alpha
Summit Therapeutics (SMMT) Advances Lung Cancer Drug with Positi - GuruFocus
Why Summit Therapeutics Plunged Today - Yahoo Finance
Summit Therapeutics: Critical NSCLC Study Readout Jeopardizes Ivonesimab Approval (SMMT) - Seeking Alpha
Summit's Shares Fall Despite Progression-Free Survival Gains in Ivonescimab Trial - marketscreener.com
Summit Therapeutics Stock Tumbles On Oncology Drug Trial Data, Retail Flags ‘Insane’ Valuation By Stocktwits - Investing.com India
Summit’s disappointing survival readout raises stakes for full data - Endpoints News
Summit Therapeutics Stock Tumbles On Oncology Drug Trial Data, Retail Flags ‘Insane’ Valuation - MSN
Summit Therapeutics Study Is a Win for China Biopharma Deals. Why the Stock Is Down. - Barron's
Summit Says Ivonescimab Significantly Improves Progression-Free Survival; Overall Survival Trend Not Statistically Significant -- Shares Drop - marketscreener.com
Akeso, Summit's ivonescimab delayed progression of certain lung cancers in first global phase 3 readout - Fierce Pharma
Summit Therapeutics Reports Mixed Trial Results for Ivonescimab in Lung Cancer Treatment - geneonline.com
Summit Therapeutics' Closely-Watched Lung Cancer Study Of Ivonescimab Misses Overall Survival Endpoint - Benzinga
Summit stock down after cancer trial data (update) (NASDAQ:SMMT) - Seeking Alpha
0.09%
1.51%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):